前列腺癌PSMA PET/CT疗效评估标准共识声明
2020年2月21日,核医学、放射学与泌尿外科专家在荷兰阿姆斯特丹开会制定转移性前列腺癌患者PSMA PET/CT疗效评估标准及最佳使用时机。专家匿名投票(1-9分)就所有声明达成共识,认为PSMA PET/CT可用于局部和全身治疗前后评估疗效,影像标准应将患者分为应答者、疾病稳定、部分缓解、完全缓解或无应答者,寡转移或多转移等特定临床场景需特殊考虑。
要点
- PSMA PET/CT可用于转移性前列腺癌患者任何局部和全身治疗前后评估治疗应答。
- PSMA PET/CT影像标准应将患者分为应答者、疾病稳定、部分缓解、完全缓解或无应答者。
- 寡转移或多转移等特定临床场景需特殊考虑。
核心结论
- 采用PSMA PET/CT应有适当使用指征和精确判读标准支持。
- PSMA PET/CT标准应将患者分为应答者或无应答者。
- 特定临床场景需特殊考虑。
研究设计与样本
- 2020年2月21日,核医学、放射学与/或泌尿外科前列腺癌专家小组在荷兰阿姆斯特丹开会制定PSMA PET/CT疗效评估标准及最佳使用时机。
- 专家会前收到主题和相关文献,制定关于如何判读PSMA PET/CT治疗应答与进展及何时使用的声明。
- 专家对声明进行匿名投票,采用九分制,从强烈不同意(1分)到强烈同意(9分),以中位评分描述同意度和共识。
主要发现
- PSMA PET/CT共识声明涉及用途、最佳执行时机、疗效评估标准、可能获益患者及放射性标记PSMA PET示踪剂处理。
- 所有声明均达成共识。
- PSMA PET/CT可用于转移性前列腺癌患者任何局部和全身治疗前后评估治疗应答。
- PSMA PET/CT影像标准理想上应将患者分为应答者、疾病稳定、部分缓解、完全缓解或无应答者。
- 寡转移或多转移等特定临床场景需特殊考虑。
关键数值与推荐
- 专家投票采用九分制,从强烈不同意(1分)到强烈同意(9分)。
- 所有声明均达成共识。
临床怎么用
- PSMA PET/CT可用于转移性前列腺癌患者任何局部和全身治疗前后评估治疗应答。
- PSMA PET/CT影像判读应将患者分为应答者、疾病稳定、部分缓解、完全缓解或无应答者。
- 寡转移或多转移等特定临床场景需特殊考虑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is used for (re)staging prostate cancer (PCa) and as a biomarker for evaluating response to therapy, but lacks established response criteria. A panel of PCa experts in nuclear medicine, radiology, and/or urology met on February 21, 2020, in Amsterdam, The Netherlands, to formulate criteria for PSMA PET/CT-based response in patients treated for metastatic PCa and optimal timing to use it. METHODS: Panelists received thematic topics and relevant literature prior to the meeting. Statements on how to interpret response and progression on therapy in PCa with PSMA PET/CT and when to use it were developed. Panelists voted anonymously on a nine-point scale, ranging from strongly disagree (1) to strongly agree (9). Median scores described agreement and consensus. RESULTS: PSMA PET/CT consensus statements concerned utility, best timing for performing, criteria for evaluation of response, patients who could benefit, and handling of radiolabeled PSMA PET tracers. Consensus was reached on all statements. PSMA PET/CT can be used before and after any local and systemic treatment in patients with metastatic disease to evaluate response to treatment. Ideally, PSMA PET/CT imaging criteria should categorize patients as responders, patients with stable disease, partial response, and complete response, or as non-responders. Specific clinical scenarios such as oligometastatic or polymetastatic disease deserve special consideration. CONCLUSIONS: Adoption of PSMA PET/CT should be supported by indication for appropriate use and precise criteria for interpretation. PSMA PET/CT criteria should categorize patients as responders or non-responders. Specific clinical scenarios deserve special consideration.
引用
- Fanti S, Goffin K, Hadaschik BA, et al. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging. 2020. PMID: 32617640. doi:10.1007/s00259-020-04934-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。